| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2016: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Outline of Final Research Achievements |
Human induced pluripotent stem (iPS) cells are expected to be applicable not only in regenerative medicine but also in drug development such as pharmacokinetic and toxicokinetic studies. In this study, the differentiation in 3D sphere culture was increased the gene expressions or the activity of drug metabolizing enzymes and improved the function of human iPS cell-derived hepatocytes. The small-molecule compounds, PD98059, 5-aza-2-deoxycytidine and A-83-01, were effective in generating pharmacokinetically functional enterocytes from human iPS cells. MEK, DNMT, and TGF-β inhibitors can be used to promote the differentiation of human iPS cells into pharmacokinetically functional enterocytes.
|
